Nektar Therapeutics (NKTR) vs Trevi Therapeutics, Inc. (TRVI)

Nektar Therapeutics and Trevi Therapeutics, Inc. are both Biotechnology companies. Nektar Therapeutics and Trevi Therapeutics, Inc. are of similar size ($2.1B and $2.1B). Trevi Therapeutics, Inc. has the higher net margin (0.00% vs −287.8%) and the lower return on invested capital (−1,412.1% vs −40.2%). Across the 13 metrics below, Trevi Therapeutics, Inc. leads on 9 and Nektar Therapeutics on 4.

Valuation

Metric NKTR TRVI Biotechnology median
P/E n/m n/m 7.88
P/S 34.55 n/m 11.47
P/B 2.09 7.02 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 26.50 n/m 10.73
Earnings yield (11.74%) (2.36%) (28.84%)
Free cash flow yield (12.41%) (2.34%) (23.03%)

Profitability

Metric NKTR TRVI Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (257.80%) 0.00% 0.00%
Net margin (287.84%) 0.00% 0.00%
Free cash flow margin (428.72%) 0.00% 0.00%
Return on equity (35.75%) (19.66%) (57.72%)
Return on assets (24.12%) (18.97%) (49.22%)
Return on invested capital (40.20%) (1,412.11%) 0.00%

Growth

Metric NKTR TRVI Biotechnology median
Revenue growth (TTM) (27.15%) — 5.64%
EPS growth (last fiscal year) (11.89%) 31.91% —
Revenue growth, 5-year CAGR (18.43%) — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NKTR TRVI Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 10.42 37.28 4.73
Net debt to EBITDA 1.77 3.83 0.96

Dividend

Metric NKTR TRVI Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric NKTR TRVI Biotechnology median
Market cap 2.14b 2.09b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack